Debra A. Tonetti - Publications

Affiliations: 
University of Illinois at Chicago, Health Sciences Center, Chicago, IL 60612, United States 
Area:
Pharmacy, Pharmacology, Cell Biology, Oncology

81 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Shete N, Calabrese J, Tonetti DA. Revisiting Estrogen for the Treatment of Endocrine-Resistant Breast Cancer: Novel Therapeutic Approaches. Cancers. 15. PMID 37509308 DOI: 10.3390/cancers15143647  0.604
2022 Pal P, Millner A, Semina SE, Huggins RJ, Running L, Aga DS, Tonetti DA, Schiff R, Greene GL, Atilla-Gokcumen GE, Frasor J. Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells. Cancers. 14. PMID 35625985 DOI: 10.3390/cancers14102380  0.568
2021 Means-Powell JA, Mayer IA, Ismail-Khan R, Del Valle L, Tonetti D, Abramson VG, Sanders MS, Lush RM, Sorrentino C, Majumder S, Miele L. A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC). Clinical Breast Cancer. 22: 103-114. PMID 34903452 DOI: 10.1016/j.clbc.2021.10.013  0.538
2020 Abderrahman B, Maximov PY, Curpan RF, Fanning SW, Hanspal JS, Fan P, Foulds CE, Chen Y, Malovannaya A, Jain A, Xiong R, Greene GL, Tonetti DA, Thatcher GRJ, Jordan VC. Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer. Molecular Cancer Therapeutics. PMID 33177154 DOI: 10.1158/1535-7163.MCT-20-0563  0.45
2020 Abderrahman B, Maximov PY, Curpan RF, Hanspal JS, Fan P, Xiong R, Tonetti DA, Thatcher GRJ, Jordan VC. Pharmacology and Molecular Mechanisms of Clinically-Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for Endocrine-Resistant Breast Cancer Treatment. Molecular Pharmacology. PMID 32788222 DOI: 10.1124/Molpharm.120.000054  0.61
2020 Dudek AZ, Liu LC, Fischer JH, Wiley EL, Sachdev JC, Bleeker J, Hurley RW, Tonetti DA, Thatcher GRJ, Venuti RP, O'Regan RM. Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy. Breast Cancer Research and Treatment. PMID 32696319 DOI: 10.1007/S10549-020-05787-Z  0.646
2020 Li Y, Zhao J, Gutgesell L, Shen Z, Ratia K, Dye K, Dubrovyskyii O, Zhao H, Huang F, Tonetti DA, Thatcher GR, Xiong R. Novel pyrrolopyridone bromodomain and extra-terminal motif (BET) inhibitors effective in endocrine-resistant ER+ breast cancer with acquired resistance to fulvestrant and palbociclib. Journal of Medicinal Chemistry. PMID 32453591 DOI: 10.1021/Acs.Jmedchem.0C00456  0.596
2020 Andreano KJ, Wardell SE, Baker JG, Desautels TK, Baldi R, Chao CA, Heetderks KA, Bae Y, Xiong R, Tonetti DA, Gutgesell LM, Zhao J, Sorrentino JA, Thompson DA, Bisi JE, et al. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Research and Treatment. PMID 32130619 DOI: 10.1007/S10549-020-05575-9  0.601
2020 O'Regan R, Hurley R, Sachdev J, Bleeker J, Tonetti D, Thatcher G, Venuti R, Dudek A. Abstract P5-11-06: Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine therapy Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-11-06  0.509
2019 Lu Y, Gutgesell L, Xiong R, Zhao J, Li Y, Rosales C, Hollas M, Shen Z, Gordon-Blake J, Dye K, Wang YT, Lee S, Chen H, He D, Dubrovyskyii O, ... ... Tonetti DA, et al. Design and Synthesis of Basic Selective Estrogen Receptor Degraders (B-SERDs) for Endocrine Therapy Resistant Breast Cancer. Journal of Medicinal Chemistry. PMID 31746603 DOI: 10.1021/Acs.Jmedchem.9B01580  0.585
2019 ORegan RM, Hurley R, Sachdev JC, Bleeker J, Tonetti D, Thatcher G, Venuti R, Dudek AZ. Abstract CT051: Phase I study of TTC-352 in patients with estrogen receptor-positive metastatic breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct051  0.45
2019 Xiong R, Li Y, Zhao J, Tonetti D, Thatcher G. Abstract 3830: Novel bromodomains and extra-terminal motif (BET) inhibitors developed against estrogen receptor positive, fulvestrant- and CDK4/6-resistant breast cancer models Cancer Research. 79: 3830-3830. DOI: 10.1158/1538-7445.Am2019-3830  0.669
2019 Xiong R, Li Y, Zhao J, Huang F, Shen Z, Lu Y, Gutgesell L, Tonetti D, Thatcher G. Basic selective estrogen receptor degraders (B-SERDs) in combination with novel BET inhibitors in ER+ breast cancer Annals of Oncology. 30: v189. DOI: 10.1093/Annonc/Mdz244.064  0.606
2018 O'Regan R, Hurley R, Sachdev JC, Tonetti DA, Thatcher GR, Venuti RP, Dudek AZ. Study TTC-352-101: Phase 1 study of TTC-352 in patients with metastatic breast cancer (BC) progressing on endocrine therapy. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps1108  0.604
2018 Gutgesell LM, Xiong R, Zhao J, Zhao H, Tonetti DA, Thatcher GR. Abstract 3744: Multiple endocrine-resistant breast cancer cell lines retain ER and sensitivity to endocrine therapy Endocrinology. 78: 3744-3744. DOI: 10.1158/1538-7445.Am2018-3744  0.568
2018 Rosales CI, Zhao J, Gutgesell LM, Xiong R, Tonetti DA, Thatcher GR. Abstract 3738: Three-dimensional treatment-resistant breast cancer spheroids as a predictive model of in vivo response to endocrine therapy Cancer Research. 78: 3738-3738. DOI: 10.1158/1538-7445.Am2018-3738  0.651
2017 Pham TND, Perez White BE, Zhao H, Mortazavi F, Tonetti DA. Protein kinase C α enhances migration of breast cancer cells through FOXC2-mediated repression of p120-catenin. Bmc Cancer. 17: 832. PMID 29216867 DOI: 10.1186/S12885-017-3827-Y  0.612
2017 White BP, Molloy ME, Zhao H, Zhang Y, Tonetti DA. Retraction Note to: Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer. Molecular Cancer. 16: 121. PMID 28716023 DOI: 10.1186/S12943-017-0697-5  0.653
2017 Xiong R, Zhao J, Gutgesell LM, Wang YT, Lee S, Karumudi B, Zhao H, Lu Y, Tonetti DA, Thatcher GR. Novel Selective Estrogen Receptor Downregulators (SERDs) Developed Against Treatment-Resistant Breast Cancer. Journal of Medicinal Chemistry. PMID 28117994 DOI: 10.1021/Acs.Jmedchem.6B01355  0.565
2017 Tonetti DA, Xiong R, Zhao J, Gutgesell L, Dudek AZ, Thatcher GR. Efficacy, maximal tolerated dose, and toxicokinetics of TTC-352 in rats and dogs, a partial ER agonist for metastatic ER+ breast cancer. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E14090  0.65
2017 Gutgesell L, Xiong R, Thatcher G, Tonetti D. Abstract P3-04-23: Combination therapy of targeted anticancer pathways and estrogen receptor ligands and their responses inde novoandtamoxifen resistant cell models Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-04-23  0.599
2017 Gutgesell LM, Xiong R, Zhao J, Tonetti DA, Thatcher GR. Abstract 3603: Optimizing combination therapy against antiestrogen-resistance in estrogen receptor positive breast cancer Endocrinology. 77: 3603-3603. DOI: 10.1158/1538-7445.Am2017-3603  0.596
2016 Zhao H, Pham T, Emmadi R, Wiley E, Warso M, Perez-Tamayo A, Salti G, Hoskins K, Tonetti DA. Abstract B19: Breast cancer patient-derived xenografts: The University of Illinois at Chicago Cancer Center experience Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-B19  0.577
2016 Xiong R, Zhao J, Gutgesell L, Tonetti D, Thatcher G. Abstract 3902: Novel selective estrogen receptor downregulators developed using endocrine-independent breast cancer cell lines Cancer Research. 76: 3902-3902. DOI: 10.1158/1538-7445.Am2016-3902  0.637
2015 Xiong R, Patel HK, Gutgesell LM, Zhao J, Delgado-Rivera L, Pham TN, Zhao H, Carlson KE, Martin TA, Katzenellenbogen JA, Moore TW, Tonetti D, Thatcher GR. Selective human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer. Journal of Medicinal Chemistry. PMID 26681208 DOI: 10.1021/Acs.Jmedchem.5B01276  0.676
2015 Asztalos S, Pham TN, Gann PH, Hayes MK, Deaton R, Wiley EL, Emmadi R, Kajdacsy-Balla A, Banerji N, McDonald W, Khan SA, Tonetti DA. High incidence of triple negative breast cancers following pregnancy and an associated gene expression signature. Springerplus. 4: 710. PMID 26618099 DOI: 10.1186/S40064-015-1512-7  0.543
2015 Rauscher GH, Kresovich JK, Poulin M, Yan L, Macias V, Mahmoud AM, Al-Alem U, Kajdacsy-Balla A, Wiley EL, Tonetti D, Ehrlich M. Exploring DNA methylation changes in promoter, intragenic, and intergenic regions as early and late events in breast cancer formation. Bmc Cancer. 15: 816. PMID 26510686 DOI: 10.1186/S12885-015-1777-9  0.446
2015 Thatcher GR, Xiong R, Patel HK, Zhao J, Liang X, Wang Y, Molloy ME, Tonetti D. Abstract P3-05-23: Novel, non-uterotrophic, selective estrogen mimics cause regression of tamoxifen-resistant breast cancer in 2D and 3D cultures and in mouse xenograft models Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-05-23  0.53
2015 Pham TN, Perez-White B, Tonetti DA. Abstract 4095: Protein kinase C alpha (PKCα) is a novel regulator of FOXC2 and p120-catenin in triple negative and endocrine resistant breast cancer Cancer Research. 75: 4095-4095. DOI: 10.1158/1538-7445.Am2015-4095  0.595
2015 Patel H, Xiong R, Gutgesell L, Zhao J, Molloy ME, Tonetti D, Thatcher GRJ. Abstract C98: Selective estrogen mimics (SEMs) for the treatment of tamoxifen resistant breast cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C98  0.694
2014 Weiss MS, Peñalver Bernabé B, Shin S, Asztalos S, Dubbury SJ, Mui MD, Bellis AD, Bluver D, Tonetti DA, Saez-Rodriguez J, Broadbelt LJ, Jeruss JS, Shea LD. Dynamic transcription factor activity and networks during ErbB2 breast oncogenesis and targeted therapy. Integrative Biology : Quantitative Biosciences From Nano to Macro. 6: 1170-82. PMID 25303361 DOI: 10.1039/C4Ib00086B  0.494
2014 Stanford JC, Young C, Hicks D, Owens P, Williams A, Vaught DB, Morrison MM, Lim J, Williams M, Brantley-Sieders DM, Balko JM, Tonetti D, Earp HS, Cook RS. Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution. The Journal of Clinical Investigation. 124: 4737-52. PMID 25250573 DOI: 10.1172/Jci76375  0.472
2014 Molloy ME, White BE, Gherezghiher T, Michalsen BT, Xiong R, Patel H, Zhao H, Maximov PY, Jordan VC, Thatcher GR, Tonetti DA. Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer. Molecular Cancer Therapeutics. 13: 2515-26. PMID 25205655 DOI: 10.1158/1535-7163.Mct-14-0319  0.605
2014 Peng M, Emmadi R, Wang Z, Wiley EL, Gann PH, Khan SA, Banerji N, McDonald W, Asztalos S, Pham TN, Tonetti DA, Tyner AL. PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors. Oncotarget. 5: 6038-48. PMID 25153721 DOI: 10.18632/Oncotarget.2153  0.51
2014 Peng M, Emmadi R, Wang Z, Wiley EL, Gann PH, Khan S, Banerji N, McDonald W, Asztalos S, Pham TN, Tonetti DA, Tyner AL. PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors. Oncotarget. PMID 25015012 DOI: 10.18632/oncotarget.2153  0.358
2014 Molloy ME, White BP, Zhao H, Michalsen BT, Patel HK, Zhao J, Xiong R, Siklos MI, Thatcher GRJ, Tonetti DA. Abstract 619: Selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer Cancer Research. 74: 619-619. DOI: 10.1158/1538-7445.Am2014-619  0.67
2014 Patel H, Xiong R, Zhao J, Molloy ME, Tonetti D, Thatcher GRJ. Abstract 2710: Lead based development and evaluation of selective estrogen mimics in tamoxifen resistant breast cancer Cancer Research. 74: 2710-2710. DOI: 10.1158/1538-7445.Am2014-2710  0.68
2014 Thatcher G, Xiong R, Patel H, Zhao J, Liang X, Wang Y, Molloy M, Tonetti D. 316 Potent, partial agonists at ERalpha as selective estrogen mimics for treatment of tamoxifen-resistant breast cancer European Journal of Cancer. 50: 103. DOI: 10.1016/S0959-8049(14)70442-3  0.634
2013 Yun J, Pannuti A, Espinoza I, Zhu H, Hicks C, Zhu X, Caskey M, Rizzo P, D'Souza G, Backus K, Denning MF, Coon J, Sun M, Bresnick EH, Osipo C, ... ... Tonetti DA, et al. Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells. Oncogenesis. 2: e60. PMID 23917222 DOI: 10.1038/oncsis.2013.26  0.751
2013 Zheng Y, Wang Z, Bie W, Brauer PM, Perez White BE, Li J, Nogueira V, Raychaudhuri P, Hay N, Tonetti DA, Macias V, Kajdacsy-Balla A, Tyner AL. PTK6 activation at the membrane regulates epithelial-mesenchymal transition in prostate cancer. Cancer Research. 73: 5426-37. PMID 23856248 DOI: 10.1158/0008-5472.Can-13-0443  0.384
2013 Perez White B, Molloy ME, Zhao H, Zhang Y, Tonetti DA. Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer. Molecular Cancer. 12: 34. PMID 23634843 DOI: 10.1186/1476-4598-12-34  0.653
2013 Ho T, Asztalos S, Majumdar N, Arslan AD, Stampfer MR, Wiley EL, Khan SA, Banerji N, McDonald W, He X, Tonetti DA, Beck WT. Abstract 4380: Splicing factor SRSF3 knockdown-induced breast cancer cell growth suppression and apoptosis is partially reversed by Z-VAD-FMK and its expression correlates malignancy of breast cancer. Cancer Research. 73: 4380-4380. DOI: 10.1158/1538-7445.Am2013-4380  0.625
2013 Arslan AD, Asztalos S, Stampfer M, Tonetti D, He X, Beck WT. Abstract 3201: PTBP1 stability is increased in ovarian and breast cancer cell lines compared to matched controls. Cancer Research. 73: 3201-3201. DOI: 10.1158/1538-7445.Am2013-3201  0.582
2012 Tonetti DA, Gao W, Escarzaga D, Walters K, Szafran A, Coon JS. PKCα and ERβ Are Associated with Triple-Negative Breast Cancers in African American and Caucasian Patients. International Journal of Breast Cancer. 2012: 740353. PMID 22500240 DOI: 10.1155/2012/740353  0.51
2012 White BEP, Zhao H, Kundu M, Molloy ME, Tonetti DA. Abstract 4216: Protein kinase C ≤ overexpression is associated with loss of membrane-associated E-cadherin and β-catenin in T47D xenograft breast tumors Cancer Research. 72: 4216-4216. DOI: 10.1158/1538-7445.Am2012-4216  0.53
2012 Pham T, Asztalos S, Weiss, Shea L, Tonetti D. Abstract P6-04-24: Overexpression of protein kinase C alpha differentially activates transcription factors in T47D breast cancer cells in the presence of 17β-estradiol both in the 2D and 3D environments. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P6-04-24  0.517
2011 Asztalos S, Gann PH, Nonn L, Balla AK, Macias V, Deaton RJ, Wiley EL, Tonetti DA. Abstract 3737: The effects of pregnancy on ERα and Her2/neu protein expression in the normal breast Cancer Research. 71: 3737-3737. DOI: 10.1158/1538-7445.Am2011-3737  0.567
2011 White BEP, Zhao H, Tonetti DA. Abstract 2339: Overexpression of PKCα in T47D breast cancer cells induces migration via p120-catenin transcriptional downregulation Cancer Research. 71: 2339-2339. DOI: 10.1158/1538-7445.Am2011-2339  0.607
2011 Kundu M, Zhang Y, Zhao H, Tonetti DA. Abstract 2301: E2-induced T47D:A18/PKCα tumor regression is accompanied by translocation of ERα to extranuclear sites in association with caveolin-1 Cancer Research. 71: 2301-2301. DOI: 10.1158/1538-7445.Am2011-2301  0.408
2011 Molloy ME, Tonetti DA. Abstract 2289: Potential role for Src kinase inhibitors in PKCα-overexpressing breast cancer Cancer Research. 71: 2289-2289. DOI: 10.1158/1538-7445.Am2011-2289  0.532
2010 Halasi M, Zhao H, Dahari H, Bhat UG, Gonzalez EB, Lyubimo AV, Tonetti DA, Gartel AL. Thiazole antibiotics against breast cancer. Cell Cycle (Georgetown, Tex.). 9: 1214-7. PMID 20410687 DOI: 10.4161/Cc.9.6.10955  0.657
2010 Asztalos S, Gann PH, Hayes MK, Nonn L, Beam CA, Dai Y, Wiley EL, Tonetti DA. Gene expression patterns in the human breast after pregnancy. Cancer Prevention Research (Philadelphia, Pa.). 3: 301-11. PMID 20179293 DOI: 10.1158/1940-6207.Capr-09-0069  0.525
2010 Han H, Frasor J, Tonetti D. Abstract 4608: Overexpression of PKCα alters gene expression pattern in T47D breast cancer cells associated with hormone-independent growth and tamoxifen resistance Endocrinology. 70: 4608-4608. DOI: 10.1158/1538-7445.Am10-4608  0.594
2009 Zhang Y, Zhao H, Asztalos S, Chisamore M, Sitabkhan Y, Tonetti DA. Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix. Molecular Cancer Research : McR. 7: 498-510. PMID 19372579 DOI: 10.1158/1541-7786.Mcr-08-0415  0.504
2009 Asztalos S, Gann P, Hayes M, Nonn L, Beam C, Wiley E, Tonetti D. Role of lobular involution in pregnancy-associated breast cancer. Cancer Research. 69: 5038. DOI: 10.1158/0008-5472.Sabcs-5038  0.557
2009 White BP, Tonetti D. T47D/PKCα Cells Are Nonmigratory and NoninvasiveIn VitroDespite Tamoxifen ResistanceIn Vivo. Cancer Research. 69: 6173-6173. DOI: 10.1158/0008-5472.Sabcs-09-6173  0.477
2009 Asztalos S, Gann P, Hayes M, Nonn L, Wiley E, Khan S, Susnik B, Diaz L, Banerji N, Tonetti D. Increased Expression of Inflammatory Genes in Pregnancy-Associated Breast Cancers. Cancer Research. 69: 5158-5158. DOI: 10.1158/0008-5472.Sabcs-09-5158  0.579
2009 Molloy M, Thatcher G, Bolton J, Tonetti D. 2-(4-Hydroxyphenyl)-Benzo[b]thiophen-6-ol, an Estrogen-Like Compound, Induces Apoptosis in T47D/PKCα Breast Cancer Cells. Cancer Research. 69: 5140-5140. DOI: 10.1158/0008-5472.Sabcs-09-5140  0.583
2009 Kundu M, Zhang Y, Zhao H, Tonetti D. Estradiol Induced Regression of T47D:A18/PKCα Tumor Involves Translocation of Estrogen Receptor alpha from the Nucleus to the Cytoplasm. Cancer Research. 69: 4140-4140. DOI: 10.1158/0008-5472.Sabcs-09-4140  0.415
2008 Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, ... ... Tonetti DA, et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Research. 68: 5226-35. PMID 18593923 DOI: 10.1158/0008-5472.Can-07-5744  0.743
2008 Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, ... ... Tonetti DA, et al. Cross-talk between Notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches (Cancer Research (July 1, 2008) 68 (5226-5235)) Cancer Research. 68: 7246. DOI: 10.1158/0008-5472.Can-68-17-Cor1  0.721
2008 Miele L, Rizzo P, Osipo C, Foreman K, Bocchetta M, Tonetti D. 6 INVITED Notch as a potential therapeutic target in cancer European Journal of Cancer Supplements. 6: 4. DOI: 10.1016/S1359-6349(08)71938-4  0.416
2007 Tonetti DA, Zhang Y, Zhao H, Lim SB, Constantinou AI. The effect of the phytoestrogens genistein, daidzein, and equol on the growth of tamoxifen-resistant T47D/PKC alpha. Nutrition and Cancer. 58: 222-9. PMID 17640169 DOI: 10.1080/01635580701328545  0.485
2006 Lin X, Yu Y, Zhao H, Zhang Y, Manela J, Tonetti DA. Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model. Carcinogenesis. 27: 1538-46. PMID 16513679 DOI: 10.1093/carcin/bgl002  0.381
2005 Constantinou AI, White BE, Tonetti D, Yang Y, Liang W, Li W, van Breemen RB. The soy isoflavone daidzein improves the capacity of tamoxifen to prevent mammary tumours. European Journal of Cancer (Oxford, England : 1990). 41: 647-54. PMID 15737570 DOI: 10.1016/J.Ejca.2004.12.005  0.32
2005 Peng X, Mehta RG, Tonetti DA, Christov K. Identification of novel RARbeta2 transcript variants with short 5'-UTRs in normal and cancerous breast epithelial cells. Oncogene. 24: 1296-301. PMID 15558014 DOI: 10.1038/Sj.Onc.1208284  0.509
2004 Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD, Beck WT. Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Research. 64: 1247-51. PMID 14973083 DOI: 10.1158/0008-5472.Can-03-3583  0.535
2004 Tonetti DA. Prevention of breast cancer by recapitulation of pregnancy hormone levels. Breast Cancer Research : Bcr. 6: E8. PMID 14680493 DOI: 10.1186/Bcr750  0.639
2003 Tonetti DA, Rubenstein R, DeLeon M, Zhao H, Pappas SG, Bentrem DJ, Chen B, Constantinou A, Craig Jordan V. Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 87: 47-55. PMID 14630090 DOI: 10.1016/J.Jsbmb.2003.07.003  0.54
2003 Liu X, Pisha E, Tonetti DA, Yao D, Li Y, Yao J, Burdette JE, Bolton JL. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites. Chemical Research in Toxicology. 16: 832-7. PMID 12870885 DOI: 10.1021/Tx030004S  0.579
2003 Tonetti DA, Morrow M, Kidwai N, Gupta A, Badve S. Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure. British Journal of Cancer. 88: 1400-1402. PMID 12778068 DOI: 10.1038/Sj.Bjc.6600923  0.442
2001 Fournier DB, Chisamore M, Lurain JR, Rademaker AW, Jordan VC, Tonetti DA. Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: possible role in AP-1-mediated proliferation of ER-negative endometrial cancer. Gynecologic Oncology. 81: 366-72. PMID 11371124 DOI: 10.1006/Gyno.2001.6164  0.63
2000 Tonetti DA, Chisamore MJ, Grdina W, Schurz H, Jordan VC. Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines British Journal of Cancer. 83: 782-791. PMID 10952784 DOI: 10.1054/Bjoc.2000.1326  0.536
1999 Tonetti DA, Jordan VC. The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens. Journal of Mammary Gland Biology and Neoplasia. 4: 401-13. PMID 10705923 DOI: 10.1023/A:1018722502034  0.636
1998 Tonetti DA, O'Regan R, Tanjore S, England G, Jordan VC. Antiestrogen stimulated human endometrial cancer growth: laboratory and clinical considerations. The Journal of Steroid Biochemistry and Molecular Biology. 65: 181-9. PMID 9699872 DOI: 10.1016/S0960-0760(98)00011-9  0.599
1998 Levenson AS, Tonetti DA, Jordan VC. The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor. British Journal of Cancer. 77: 1812-9. PMID 9667651 DOI: 10.1038/Bjc.1998.301  0.463
1997 Jordan VC, MacGregor JI, Tonetti DA. Tamoxifen: from breast cancer therapy to the design of a postmenopausal prevention maintenance therapy. Clinical Oncology. 9: 390-394. PMID 9448968 DOI: 10.1016/S0936-6555(97)80134-3  0.523
1997 Tonetti DA, Jordan VC. The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer. The Journal of Steroid Biochemistry and Molecular Biology. 62: 119-28. PMID 9393947 DOI: 10.1016/S0960-0760(97)00034-4  0.632
1997 Jordan VC, MacGregor JI, Tonetti DA. Tamoxifen: From breast cancer therapy to the design of a postmenopausal prevention maintenance therapy Osteoporosis International. 7: 52-57. PMID 9205647 DOI: 10.1007/Bf01674814  0.523
1996 Tonetti DA, Jordan VC. Targeted anti-estrogens to treat and prevent diseases in women Molecular Medicine Today. 2: 218-223. PMID 8796891 DOI: 10.1016/1357-4310(96)88775-2  0.538
1995 Tonetti DA, Jordan VC. Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. Anti-Cancer Drugs. 6: 498-507. PMID 7579553 DOI: 10.1097/00001813-199508000-00002  0.567
Show low-probability matches.